Vitruvias Therapeutics Inc. Completes Series A Preferred Financing Led by JW Asset Management and Perceptive Advisors

Posted by on Jan 6, 2018

AUBURN, AL. – Vitruvias Therapeutics Inc., a private generic pharmaceutical company with a focus on sterile injectables, announced today the completion of a $11.5 million Series A preferred financing. The investment was led by JW Asset Management LLC, and Perceptive Advisors.

The Company is also pleased to announce that Jason Wild of JW Asset Management, Michael Altman of Perceptive Advisors and Ed Schutter, CEO of Arbor Pharmaceuticals, Inc., will be appointed to the Company’s Board of Directors.

Carl Whatley, President of Vitruvias commented, “having the financial strength and industry knowledge of both JW Asset Management and Perceptive Advisors is a significant event for our company. We are excited that these informed investors recognized the potential for Vitruvias, and appreciate the confidence they have expressed in the management team.” In addition to Mr. Whatley, Vitruvias is led by Bryce Harvey and Roger Graben, PhD. This team previously founded and built both ProEthic Pharmaceuticals and Midlothian Laboratories, which were eventually acquired by the Kowa Company Ltd., and Mayne Pharmaceuticals, respectively.

Jason Wild, President and Chief Investment Officer of JW Asset Management added, “We are impressed with what the entrepreneurial team at Vitruvias has accomplished thus far, and look forward to being part of their future success. We have known both Carl and Bryce since their early days at ProEthic and Midlothian, and are excited to have an opportunity to work with them and their team.”

Vitruvias Therapeutics will primarily use this investment to complete multiple projects already under development. The company recently received approval for its first ANDA product which it expects to launch in early 2018. The company also has several other ANDAs, either filed with the FDA, or in various stages of development.

Leave a Reply